Hi, I'm 55 and have high cholesterol. I've been on Lipitor, Zocor and Provacol. They have tested me several times in recent years, and the statin drugs are messing up my liver enzymes. My new doctor is planning on putting me on Zetia. Now I'm hearing there are concerns about Zetia. Do you know what they are concerned about?
U.S. stocks looked set for a mixed start on the last day of the quarter, as investors await a Bush administration plan aimed at overhauling regulation on Wall Street amid a meltdown in the financial sector.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.